Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01598987 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A Phase 3 study of Liver Transplant and Renal Function, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT01598987 is a Phase 3 study of Liver Transplant and Renal Function that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 56 participants, below the 5,455-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT01598987, a Phase 3 study of Liver Transplant and Renal Function, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
Conditions Studied
Interventions
- DRUG Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Study Locations (20)
Other
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - København Ø
- Novartis Investigative Site - Bron
- Novartis Investigative Site - Bonn
- Novartis Investigative Site - Essen
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Regensburg
- Novartis Investigative Site - Tübingen
California
- Novartis Investigative Site - Los Angeles
Connecticut
- Novartis Investigative Site - New Haven
Illinois
- Novartis Investigative Site - Chicago
Missouri
- Novartis Investigative Site - St Louis
New York
- Novartis Investigative Site - New York
South Carolina
- Novartis Investigative Site - Charleston
Texas
- Novartis Investigative Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01598987
The ClinicalTrials.gov registry entry for NCT01598987 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,455-participant average among 19 other Liver Transplant trials with a reported enrollment target (99% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Liver Transplant appearing as the primary indexed condition, and to 1 intervention - of which Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation. is the first listed.
NCT01598987 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01598987 about?
NCT01598987 is a clinical study titled "Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.". This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
What is the current status of trial NCT01598987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2012-10. Estimated completion is 2016-06.
What conditions does trial NCT01598987 study?
This clinical trial studies the following conditions: Liver Transplant, Renal Function.
What interventions are being tested in trial NCT01598987?
The interventions under investigation include: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation. (DRUG).
Who is sponsoring clinical trial NCT01598987?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01598987 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
RECRUITING · Phase 2
-
US National OCS Liver Perfusion (OLP) Registry
RECRUITING
-
Liver Transplant CGM
RECRUITING
-
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
RECRUITING · NA
-
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
RECRUITING · Phase 2
-
EVR and EPO for Liver Transplant Tolerance
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.